Seegene

Illumina Ventures led the round for the Santa Clara, California-based firm, which is developing applications for its optical detection technology.

The test was already authorized for use in Canada and South Korea. Seegene has sold more than 10 million of the assay in more than 60 countries.

Seegene said Monday that the Health Canada approval will enable hospitals and licensed labs there to run the assay immediately for high-volume testing.

The single-tube real-time PCR-based test has also received CE marking, according to Seegene, and is now commercially available.

Invitae said this week that it completed its acquisition of Singular Bio on June 19.

QuantuMDx and Molbio Diagnostics said this week they have signed a memorandum of understanding to work jointly in infectious disease diagnostics.

Through the joint collaboration, Seegene plans to accelerate development of its random access system on Hamilton's automated liquid handling platforms.